NCT07610005 A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 20 participants in total. It began in 2026-05-21 with a primary completion date of 2026-06.

Brief Summary

This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.

Eligibility Criteria

Inclusion Criteria: * Healthy, adult, female of non childbearing potential or male, 18 to 55 years of age, inclusive, at the screening visit * Male participants must follow protocol-specified contraception guidance * Continuous non-smoker who has not used nicotine and tobacco containing products for at least 3 months prior to the first dosing * BMI ≥ 18.0 and ≤ 32.0 kg/m2 and with a body weight \> 50 kg at the screening visit * Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, and ECGs, as deemed by the PI or designee * Able to swallow multiple capsules Exclusion Criteria: * Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study * History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee * History of any illness that, in the opinion of the PI or designee might confound the results of the study or poses an additional risk to the participant by their participation in the study * History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing * History or presence of hypersensitivity or idiosyncratic reaction to varegacestat or related compounds * History or presence of: * Autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus * Thrombophlebitis or deep vein thrombosis * Hematologic or coagulation disorders * Liver disease or dysfunction; Gilbert's syndrome * Renal dysfunction or glomerulonephritis * Cancer (except treated basal cell carcinoma of the skin and cancer-free for 5 years, non metastatic basal or squamous cell carcinoma of the skin, and cervical carcinoma in situ) * Clinically significant cardiovascular, gastrointestinal, pulmonary, endocrine, central nervous system disorders, or other major active and uncontrolled disease in the opinion of the PI or designee.

Contact & Investigator

Frequently Asked Questions

Related Trials